At the 2023 American Society of Retina Specialists meeting in Seattle, Washington, we asked some of the presenters, "What research here do you find exciting or interesting?" Here's what Ursula Schmidt-Erfurth, MD, Veena Raiji, MD, and Dante Pieramici, MD had to say!
"What research at the 2023 ASRS meeting do you find exciting or interesting?" Here's what Aaron Lee, MD, Megan Baldwin, PhD, and Carl Danzig, MD had to say!
Megan Baldwin, PhD, CEO and managing director of Opthea Limited, spoke with our team about the company's clinical trial drug OPT-302 (sozinibercept) at the 2023 ASRS annual meeting.
At the 2023 ASRS annual meeting, Aleksandra Rachiskaya, MD, spoke about time to fluid control with faricimab arms complete compared to aflibercept in recent studies.
At the 2023 ASRS annual meeting in Seattle, Washington, Ursula Schmidt-Erfurth, MD, shared the latest information on the GALE extension study.
Durga Borkar, MD, MMCi, discussed the FARETINA-DME study during the 2023 ASRS meeting in Seattle, Washington.
Fernando Arevalo, MD, PhD, FACS, FASRS, shared information on his presentation on the treatment of progressively symptomatic retinal detachments associated to retinoschisis cases at the 2023 ASRS annual meeting.
At the 2023 ASRS annual meeting, Dante Pieramici, MD, spoke with our team to share information on OPT-302, or sozinibercept, for the treatment of neovascular AMD and other retinal vascular diseases.
Our team spoke with Shawn Kavoussi, MD, at the 2023 ASRS meeting in Seattle, Washington about his research on using infrared video for vitreous opacities and comparing postoperative reduction in vitreous opacity scores using infrared video with the Heidelberg spectralis unit.
Michael Ip, MD, spoke with our team at the 2023 ASRS meeting in Seattle, Washington. He noted presentations and trends that are key at this event and why they're vital to a modern view of ophthalmology.
Diana Do, MD, spoke with our team at the 2023 ASRS meeting in Seattle, Washington, to discuss the 2-year data on the PHOTON study, which involved 8 milligrams of aflibercept for diabetic macular oedema.
Carl Danzig, MD, shared the exciting results of the GATHER 1 and GATHER 2 clinical trials for avacincaptad pegol for the treatment of geographic atrophy at the 2023 ASRS meeting.
At the 2023 ASRS meeting in Seattle, Washington, Aaron Lee, MD, shared how new techniques are expanding the options for deep learning in ophthalmology.
Richard B. Rosen, MD, shared insights from his presentation from ASRS 2023 on "New 'MacGyver-inspired' endolaser option for chandelier-assisted scleral buckles" with Sheryl Stevenson, our Group Editorial Director.
Cindy Cai, MD, shared insights from her presentation from ASRS 2023, "Health disparities in lapses in diabetic retinopathy care," with Sheryl Stevenson, our Group Editorial Director.
Mark Breazzano, MD, FACS, who is presenting Outcomes and Clinical Features Predictive of Fungal Endophthalmitis at the 2023 ASRS meeting in Seattle, Washington spoke with our team about this research.
Jennifer I. Lim, MD, FARVO, FASRS shares insights from her presentation on "Detection of early diabetic retinopathy using OCT-A blood flow analysis."
Our team caught up with Baruch Kupperman, MD, PhD to learn about his ASRS presentation, "Improving vision and dry AMD matching mechanism with the right patient population and stage of disease."
At ASRS 2022, Dr Sally Ong presented a talk entitled, “Vitrectomy vs Vitrectomy With Scleral Buckling in the Treatment of Giant Retinal Tear Related Retinal Detachments: International Multicentre Study.” Here she shares the biggest takeaways.
Dr Timothy G. Murray discusses the 5-year followup data from a large, consecutive case series of combined anterior and posterior segment surgery and the benefits of a single procedure for the recovery of vision and decreased risk.
Dr Nathan Steinle discusses top-line results of the OAKS and DERBY trials, testing the efficacy of pegcetacoplan for the treatment of geographic atrophy.
Dr Carl Regillo takes us through the history of the port delivery system, from ideation to US FDA approval.
Dr Victor Gonzalez discusses his presentation at ASRS, regarding 0.19mg fluocinolone acetonide implants in diabetic macular oedema (DMO) patients.
In his presentation at ASRS 2021, Dr Michael Singer divulges the results of the phase 2 study of formulations used to decrease macular oedema in patients with retinal vein occlusion.
Dr W. Lloyd Clark discusses his presentation at ASRS 2021, "Impact of nonperfusion and leakage areas on diabetic macular oedema/vision-threatening complications in nonproliferative diabetic retinopathy (NPDR)."
Dr Leo Kim discusses his presentation at ASRS 2021, entitled "Rho-kinase inhibition on an in vitro patient-derived model of proliferative vitreoretinopathy."
Dr Ankur Shah discusses key highlights of his presentation titled "YUTIQ CALM: a real-world registry study of the fluocinolone acetonide intravitreal implant 0.18 mg in chronic non-infectious posterior uveitis," during ASRS 2021.
Dr Justis P. Ehlers discusses the findings from a higher-order OCT analysis for inflammatory signal biomarkers in the HAWK Study.
Dr Caroline Baumal provides an overview of the efficacy, safety and durability of faricimab in diabetic macular oedema (DMO) at ASRS 2021.
